Inducing tolerance to a soluble foreign antigen by encapsulated cell transplants

Molecular Therapy

Volumn 13, Issue 2, 2006, Pages 447-456

  Blanco Bose, William E ^a,b   Schneider, Bernard L ^a,c   Aebischer, Patrick ^a  

^a EPFL   (Switzerland)

^b SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Allogeneic transplantation; Encapsulation; Immune response; Soluble proteins; Tolerance

Indexed keywords

ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; ERYTHROPOIETIN ANTIBODY; POLYETHERSULFONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CELL BASED GENE THERAPY; CELL ENCAPSULATION; CELL TRANSPLANTATION; CONTROLLED STUDY; FEMALE; IMMUNOLOGICAL TOLERANCE; MOUSE; MYOBLAST; NONHUMAN; PROTEIN ENGINEERING; PROTEIN SECRETION;

ANIMALS; ANTIGENS; CELLS, CULTURED; CLONAL ANERGY; ERYTHROPOIETIN, RECOMBINANT; HUMANS; IMMUNE TOLERANCE; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MYOBLASTS; SOLUBILITY;

ANIMALIA;

EID: 30344440727     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.08.010     Document Type: Article

References (39)

1. H. Schellekens Bioequivalence and the immunogenicity of biopharmaceuticals Nat. Rev. Drug Discovery 1 2002 457-462
2. H. Schellekens Immunogenicity of therapeutic proteins: Clinical implications and future prospects Clin. Ther. 24 2002 1720-1740
3. A. Kromminga and H. Schellekens Antibodies against erythropoietin and other protein-based therapeutics: An overview Ann. N. Y. Acad. Sci. 1050 2005 257-265
4. H. Schellekens and N. Casadevall Immunogenicity of recombinant human proteins: Causes and consequences J. Neurol. 251 Suppl. 2 2004 II4-II9
5. N. Casadevall Antibodies against rHuEPO: Native and recombinant Nephrol. Dial. Transplant. 17 Suppl. 5 2002 42-47
6. N. Casadevall et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin N. Engl. J. Med. 346 2002 469-475
7. D.M. DiMichele Immune tolerance: A synopsis of the international experience Haemophilia 4 1998 568-573
8. D.M. DiMichele and B.L. Kroner The North American immune tolerance registry: Practices, outcomes, outcome predictors Thromb. Haemostasis 87 2002 52-57
9. J. Wight and M. Richards Very high cost treatment for a single individual-A case report J. Public Health Med. 25 2003 4-7
10. W.W. Hancock et al. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection Proc. Natl. Acad. Sci. USA 93 1996 13967-13972
11. C.P. Larsen eta l. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways Nature 381 1996 434-438
12. C.P. Larsen et al. CD40-gp39 interactions play a critical role during allograft rejection: Suppression of allograft rejection by blockade of the CD40-gp39 pathway Transplantation 61 1996 4-9
13. D.C. Parker et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand Proc. Natl. Acad. Sci. USA 92 1995 9560-9564
14. M.M. Durham et al. Cutting edge: Administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning J. Immunol. 165 2000 1-4
15. T.G. Markees et al. Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand Transplantation 64 1997 329-335
16. X.X. Zheng et al. Blockade of CD40L/CD40 costimulatory pathway in a DST presensitization model of islet allograft leads to a state of allo-Ag specific tolerance and permits subsequent engraftment of donor strain islet or heart allografts Transplant. Proc. 31 1999 627-628
17. C.D. Gimmi G.J. Freeman J.G. Gribben G. Gray and L.M. Nadler Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation Proc. Natl. Acad. Sci. USA 90 1993 6586-6590
18. C. Chen and N. Nabavi In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2 Immunity 1 1994 147-154
19. R.J. Benjamin and H. Waldmann Induction of tolerance by monoclonal antibody therapy Nature 320 1986 449-451
20. S.X. Qin et al. Induction of tolerance in peripheral T cells with monoclonal antibodies Eur. J. Immunol. 20 1990 2737-2745
21. L. Graca A. Le Moine S.P. Cobbold and H. Waldmann Dominant transplantation tolerance Curr. Opin. Immunol. 15 2003 499-506
22. T. Wekerle J. Kurtz S. Bigenzahn Y. Takeuchi and M. Sykes Mechanisms of transplant tolerance induction using costimulatory blockade Curr. Opin. Immunol. 14 2002 592-600
23. R.E. Hargreaves N.J. Monk and S. Jurcevic Selective depletion of activated T cells: The CD40L-specific antibody experience Trends Mol. Med. 10 2004 130-135
24. N.J. Monk et al. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade Nat. Med. 9 2003 1275-1280
25. B.L. Schneider F. Schwenter W.F. Pralong and P. Aebischer Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery Mol. Ther. 7 2003 506-514
26. E. Regulier B.L. Schneider N. Deglon Y. Beuzard and P. Aebischer Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts Gene Ther. 5 1998 1014-1022
27. S.K. Tripathy H.B. Black E. Goldwasser and J.M. Leiden Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors Nat. Med. 2 1996 545-550
28. T. Loudovaris B. Charlton R.J. Hodgson and T.E. Mandel Destruction of xenografts but not allografts within cell impermeable membranes Transplant. Proc. 24 1992 2291-2292
29. A. Tibell et al. Survival of macroencapsulated allogeneic parathyroid tissue one year after transplantation in nonimmunosuppressed humans Cell Transplant 10 2001 591-599
30. + T cells can trigger allograft rejection J. Immunol. 165 2000 1111-1118
31. J. Trambley et al. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection J. Clin. Invest. 104 1999 1715-1722
32. B.L. Schneider G. Peduto and P. Aebischer A self-immunomodulating myoblast cell line for erythropoietin delivery Gene Ther. 8 2001 58-66
33. R.J. Benjamin S.X. Qin M.P. Wise S.P. Cobbold and H. Waldmann Mechanisms of monoclonal antibody-facilitated tolerance induction: A possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination Eur. J. Immunol. 18 1988 1079-1088
34. + T cells persist in vivo following induction of peripheral tolerance J. Immunol. 160 1998 4719-4729
35. W.L. Redmond B.C. Marincek and L.A. Sherman Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo J. Immunol. 174 2005 2046-2053
36. B. Sommer et al. Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts Mol. Ther. 6 2002 155-161
37. D. Yaffe and O. Saxel Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle Nature 270 1977 725-727
38. J.A. Koepke Microhematocrit method in: J.A. Koepke (Eds) Practical Laboratory Hematology 1991 Churchill Livingstone New York 112-114
39. W. Jelkmann The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP Eur. J. Haematol. 69 2002 265-274